Updated on 2026/02/26

写真a

 
HASHIMOTO Hiroya
 
Organization
Graduate School of Medicine Program in Integrated Medicine Clinical Pharmacology Associate Professor
Title
Associate Professor
External link

Degree 1

  1. Doctor (Science) ( 2013.3   Ritsumeikan University ) 

Research Interests 4

  1. 生存時間解析

  2. Biometrics

  3. Probability theory

  4. 臨床試験デザイン

Research Areas 3

  1. Life Science / Healthcare management, medical sociology

  2. Natural Science / Applied mathematics and statistics

  3. Informatics / Statistical science

Research History 3

  1. Nagoya University   Department of Biostatistics, Graduate School of Medicine   Associate Professor

    2026.1

      More details

  2. National Hospital Organization Nagoya Medical Center   Department of Clinical Research Promotion, Clinical Research Center   Chief, Laboratory of Biostatistics

    2023.8 - 2025.12

      More details

  3. National Hospital Organization Nagoya Medical Center   Department of Clinical Research Management, Clinical Research Center   Chief, Division of Statistical Analysis

    2024.5 - 2025.12

      More details

Professional Memberships 3

  1. International Society for Clinical Biostatistics

      More details

  2. International Biometric Society

      More details

  3. THE BIOMETRIC SOCIETY OF JAPAN

      More details

Committee Memberships 2

  1. 国立病院機構名古屋医療センター   研究倫理審査委員会  

    2025.9 - 2025.12   

      More details

  2. 日本小児がん研究グループ(JCCG)   生物統計委員会 委員  

    2016.12   

      More details

    Committee type:Other

    researchmap

 

Papers 11

  1. Comparison of Epiretinal Membrane Detection Rates Between Optos<sup>®</sup> and Clarus<sup>™</sup> Ultra-Widefield Fundus Imaging Systems

    Satoshi Kuwayama, Yoshio Hirano, Arisa Shibata, Hiroaki Sugiyama, Nariko Soga, Kihei Yoshida, Takaaki Yuguchi, Ryo Kurobe, Akiyo Tsukada, Shuntaro Ogura, Hiroya Hashimoto, Tsutomu Yasukawa

    Journal of Clinical Medicine     2026.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/jcm15020883

    researchmap

  2. High Serum TSLP Is Characteristic of Late-Onset, Long-Duration, Eosinophilic Asthma.

    Suzukawa M, Ohta K, Tashimo H, Narumoto O, Hashimoto H, Kita T, Takato H, Nagase H, Kobayashi K, Yamaguchi M, Abe M, Ito R, Endo T, Yanai H, Chibana K, Hizawa N, Tanimoto Y, Takagi K, Oguma T, Harada N, Sagara H, Kato A, Takata S, Komase Y, Hyodo K, Matsunaga K, Tsujino K, Niimi A, Wakamatsu K, Sugiura H, Sakakibara Y, Kamimura M, Shibata Y, Tanaka G, Nakamoto K, Tamaki S, Minakata Y, Numata T, Saito AM, Kobayashi N, Taniguchi M, TNH‐Azma Research Group (TARG)

    Allergy     2025.10

     More details

    Publishing type:Research paper (scientific journal)  

    <h4>Background</h4>Thymic stromal lymphopoietin (TSLP) is a master regulator of type 2 immune responses; however, the associations between serum TSLP and the characteristics of adult asthma have not been fully clarified. The aim of this study was to determine the characteristics of adult asthma with high serum TSLP and explore TSLP's association with the late-onset eosinophilic asthma phenotype.<h4>Methods</h4>Baseline data of the TNH-Azma study (a real-world observational cohort study conducted in Japan on 1344 patients with asthma from 30 hospitals) was used and serum cytokines were measured. Patients were stratified into quartile groups based on the baseline serum TSLP levels, and their clinical characteristics were compared. Multivariable regression analyses were used to determine clinical variables associated with serum TSLP and cytokines associated with the late-onset eosinophilic asthma phenotype.<h4>Results</h4>Patients with TSLP-high asthma were older, late-onset, eosinophilic, and less atopic; had a higher BMI; more smoking history; and more asthma-COPD overlap, sleep apnea syndrome (SAS), hypertension, and heart disease. They also exhibited lower lung function with worse asthma symptoms and were more frequently on oral corticosteroids. Multivariable regression analyses adjusted for age and sex demonstrated that a high TSLP level was positively associated with later asthma onset, longer asthma duration, hypertension, higher blood eosinophils, BMI, smoking history, use of biologics, SAS, and high Fres, and was negatively associated with pollinosis. Among the serum cytokines, TSLP exhibited the strongest association with late-onset, eosinophilic asthma.<h4>Conclusion</h4>High serum TSLP is a distinctive feature of late-onset, long-duration, eosinophilic asthma. Patients with asthma with this feature may be a unique target population for specific asthma therapy.

    DOI: 10.1111/all.70109

    PubMed

    researchmap

  3. Association of Heavy Smoking With High Body Mass Index and Cardiovascular Risk Score in Japan Reviewed

    Katsushi Takeda, Daisuke Aotani, Hiroya Hashimoto, Keiko Hamada, Chie Hasegawa, Yuki Shimizu, Yusuke Kuga, Takemasa Ando, Takashi Yagi, Hiroyuki Koyama, Hiroshi Takagi, Shigehiro Shiraki, Takashi Yokochi, Takeshi Kamiya, Hiromi Kataoka, Tomohiro Tanaka

    Obesity Science &amp; Practice     2025.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    <jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Although smoking, an established cardiovascular disease (CVD) risk, is a modifier of body mass index (BMI), studies are still lacking addressing a potential association between smoking and BMI or BMI‐related risk factors in Asia. The aim of this study was to investigate the association between smoking and BMI or CVD risk factors in a working‐age population in Japan.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Eight thousand eight hundred thirty‐six male and seven thousand three hundred seventy female health checkup examinees in a single center without self‐reported heart disease or stroke were analyzed by multiple regression analysis for an association between the smoking status (never, current, or past) or the number of cigarettes consumed (never (0/day), mild (&lt; 10/day), moderate (10–19/day) or heavy (≧ 20/day)) and age‐adjusted BMI. In subgroups of 3430 males and 2407 females, the predictive risk score of CVD from the Hisayama study except for the smoking item was calculated and compared among groups with different smoking habits.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In the analysis of the association between smoking and BMI, age‐adjusted BMI was significantly higher in heavy smokers than never, mild, or moderate smokers in males (<jats:italic>p</jats:italic> &lt; 0.01 vs. never, <jats:italic>p</jats:italic> &lt; 0.05 vs. mild, <jats:italic>p</jats:italic> &lt; 0.01 vs. moderate). Past smokers exhibited a higher CVD risk score than never or current smokers (<jats:italic>p</jats:italic> &lt; 0.01 vs. never, <jats:italic>p</jats:italic> &lt; 0.01 vs. current). Even though the score of the smoking item was excluded from the calculation, heavy smokers showed a significantly higher CVD risk score than the other three groups in males (<jats:italic>p</jats:italic> &lt; 0.01 vs. never, <jats:italic>p</jats:italic> &lt; 0.05 vs. mild, <jats:italic>p</jats:italic> &lt; 0.01 vs. moderate). This was accompanied by the deterioration of CVD risk factors, including diabetes, dyslipidemia, proteinuria, and lack of exercise habit.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Smoking status or the number of cigarettes was associated with age‐adjusted BMI or CVD risk factors in Japanese males.</jats:p></jats:sec>

    DOI: 10.1002/osp4.70089

    researchmap

  4. Comprehensive and Advanced T Cell Cluster Analysis for Discriminating Seropositive and Seronegative Rheumatoid Arthritis Reviewed

    Shinji Maeda, Hiroya Hashimoto, Tomoyo Maeda, Shin-ya Tamechika, Taio Naniwa, Akio Niimi

    Frontiers in Immunology     2025.7

     More details

    Publishing type:Research paper (scientific journal)  

    <jats:sec><jats:title>Objective</jats:title><jats:p>Rheumatoid arthritis (RA) is classified into seropositive (SP-RA) and seronegative (SN-RA) types, reflecting distinct immunological profiles. This study aimed to identify the T cell phenotypes associated with each type, thereby enhancing our understanding of their unique pathophysiological mechanisms.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We analyzed peripheral blood T cells from 50 participants, including 16 patients with untreated SP-RA, 17 patients with SN-RA, and 17 healthy controls, utilizing 25 T cell markers. For initial analysis, a dataset was established through manual T cell subset gating analysis. For advanced analysis, two distinct datasets derived from a self-organizing map algorithm, FlowSOM, were used: one encompassing all CD3+ T cells and another focusing on activated T cell subsets. Subsequently, these datasets were rigorously analyzed using adaptive least absolute shrinkage and selection operator in conjunction with leave-one-out cross-validation. This approach enhanced analysis robustness, identifying T cell clusters consistently discriminative between SP-RA and SN-RA.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Our analysis revealed significant differences in T cell subsets between RA patients and healthy controls, including elevated levels of activated T cells (CD3+, CD4+, CD8+) and helper subsets (Th1, Th17, Th17.1, and Tph cells). The Tph/Treg ratio was markedly higher in SP-RA, underscoring an effector-dominant immune imbalance. FlowSOM-based clustering identified 44 unique T cell clusters, six of which were selected as discriminative T cell clusters (D-TCLs) for distinguishing SP-RA from SN-RA. TCL21, an activated Th1-type Tph-like cell, was strongly associated with SP-RA’s aggressive profile, while TCL02, a central memory CD4+ T cell subset, displayed ICOS+, CTLA-4low+, PD-1low+, and CXCR3+, providing insights into immune memory mechanisms. Additionally, TCL31 and TCL35, both CD4−CD8− T cells, exhibited unique phenotypes: CD161+ for TCL31 and HLA-DR+CD38+TIM-3+ for TCL35, suggesting distinct pro-inflammatory roles. Support vector machine analysis (bootstrap n = 1000) validated the D-TCLs’ discriminative power, achieving an accuracy of 86.2%, sensitivity of 85.7%, and specificity of 80.9%.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This study advances our understanding of immunological distinctions between SP-RA and SN-RA, identifying key T cell phenotypes as potential targets for SP-RA disease progression. These findings provide a basis for studies on targeted therapeutic strategies tailored to modulate the markers and improve treatment for SP-RA.</jats:p></jats:sec>

    DOI: 10.3389/fimmu.2025.1491041

    researchmap

  5. Effect of Riociguat on Exercise Following Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension in Japan (THERAPY-HYBRID-BPA): A Multicentre, Double-blind, Randomised, Controlled, Phase 4 Trial. Reviewed

    Shimokawahara H, Nishizaki M, Inami T, Kubota K, Taniguchi Y, Miyagi A, Kikuchi H, Goda A, Miyanaga S, Hashimoto H, Saito AM, Sekimizu M, Matsubara H

    The Lancet. Respiratory medicine     2025.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/s2213-2600(25)00127-4

    PubMed

    researchmap

  6. Intermittent versus Daily Therapy for Noncavitary &lt;i&gt;Mycobacterium avium&lt;/i&gt; Complex Pulmonary Disease: An Open-label Randomized Trial. Reviewed International journal

    Taku Nakagawa, Fujita K, mari miki, Ito A, Ho Namkoong, Takanori Asakura, Kozo Morimoto, Hasegawa N, Kita T, Watanabe A, Tsuyuguchi K, Kawashima M, Shiozawa A, Watanabe S, Sato A, Kato T, Yoshifumi Kimizuka, Harada H, Fujita K, Saito AM, Hashimoto H, Yoshikazu Inoue, Ogawa K

    Annals of the American Thoracic Society   Vol. 22 ( 8 ) page: 1183 - 1192   2025.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    <b>Rationale</b>: Patients with noncavitary nodular bronchiectatic (NB) <i>Mycobacterium avium</i> complex pulmonary disease (MAC-PD) are treated intermittently three times a week, although no randomized controlled trials have been conducted comparing three times weekly to daily therapy. <b>Objectives</b>: To assess the tolerability, safety, and efficacy of intermittent versus daily treatment in patients with previously untreated noncavitary NB MAC-PD <b>Methods</b>: In an open-label study, patients were randomly assigned to the intermittent therapy group receiving clarithromycin 1000 mg, rifampicin 600 mg, and ethambutol 25 mg/kg (maximum 1000 mg) three days a week, or the daily therapy group receiving clarithromycin 800 mg, rifampicin 450 mg, and ethambutol 15 mg/kg (maximum 750 mg) daily for one year. The primary endpoint was the proportion of patients requiring modification of the initial treatment regimen. <b>Results</b>: Twenty-one Japanese hospitals participated in the study, enrolling 141 patients between May 2019 and December 2021. The full analysis set included 138 participants (intermittent therapy = 70; daily therapy = 68). There were no significant differences between the intermittent and daily therapy groups in terms of the regimen modification rate (20.0% (14/70) versus 33.8% (23/68); adjusted odds ratio 0.48, 95% confidence interval 0.22 to 1.05; p=0.06) or culture conversion (70.3% vs. 80.0%, p=0.53), time to culture conversion (28.0 vs. 28.5 days, p=0.89), improvement in chest CT findings (60.9% vs. 71.0%, p=0.30), or clarithromycin resistance development (1.4% vs. 0%, p=1.00). Elevated AST (16.9% vs. 41.2%, p=0.003) and ALT (18.3% vs. 44.1%, p=0.002) were more common in the daily treatment group, while elevated bilirubin (11.3% vs. 1.5%, p=0.04) and dysgeusia (14.1% vs. 1.5%, p=0.01) were more common in the intermittent treatment group. The daily treatment group exhibited a greater absolute change in the 36-Item Short Form Survey physical aspect score (-2.5 points) than the intermittent treatment group (2.1 points) (p=0.01). <b>Conclusion</b>: Intermittent treatment was not significantly better tolerated than daily treatment for noncavitary NB MAC-PD. However, further studies with larger numbers of patients are needed. Clinical trial registration available at: https://jrct.niph.go.jp/en-top. ID: jRCTs031190008.

    DOI: 10.1513/annalsats.202406-626oc

    DOI: 10.1513/AnnalsATS.202406-626OC

    Web of Science

    PubMed

    researchmap

  7. Clinical and Genetic Characteristics Based on the Japanese Patient Registry for Facioscapulohumeral Muscular Dystrophy: A Nationwide Analysis Reviewed International journal

    Tsuyoshi Matsumura, Hiroya Hashimoto, Hotake Takizawa, Wakako Yoshioka, Madoka Mori-Yoshimura, Yoshihiko Saito, Ichizo Nishino, Harumasa Nakamura

    Neuromuscular Disorders   Vol. 50   page: 105346 - 105346   2025.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The Japanese patient registry for facioscapulohumeral muscular dystrophy (FSHD) was launched in September 2020, enrolling patients genetically confirmed to have FSHD. This study aimed to analyze clinical and genetic characteristics based on data from the Japanese FSHD registry. Core items were collected from the TREAT-NMD FSHD dataset, version 1.0. By the end of June 2024, over 200 patients were enrolled, with 161 successfully registered after confirmation. Among them, 156 had FSHD1 and 5 had FSHD2; 81 had affected family members; 116 were ambulatory; 73 had respiratory dysfunction; 22 required mechanical ventilation; 8 had cardiac dysfunction; 4 had retinopathy; and 22 had hearing loss. In patients with FSHD1, the median number of D4Z4 repeats was four, with a low proportion of long repeats. D4Z4 repeat counts influenced age at disease onset, site-specific muscle weakness onset, respiratory function, retinopathy, and hearing loss. Notably, female patients were more likely to have early facial weakness and hearing loss. Our data suggest population diversity in D4Z4 repeat numbers and sex differences. We aim to collaborate with patient groups to enroll more participants and gather more accurate epidemiological data, including cases of FSHD2. Additionally, we plan to investigate racial differences through international collaboration.

    DOI: 10.1016/j.nmd.2025.105346

    Web of Science

    PubMed

    researchmap

  8. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% Reviewed International journal

    Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, Yasushi Fukuda, Akihiro Bessho, Tadaaki Yamada, Yukihiro Toi, Tomoki Kimura, Hiroshige Yoshioka, Koichi Azuma, Naoki Furuya, Yasutaka Fukui, Akiko M. Saito, Nobuyuki Yamamoto, Hideo Saka, Masashi Kondo

    JTO Clinical and Research Reports   Vol. 6 ( 3 ) page: 100784 - 100784   2025.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtocrr.2024.100784

    Web of Science

    Scopus

    PubMed

    researchmap

  9. The preferable position for quantifying left ventricular diameter by transthoracic echocardiography

    Nakayama, T; Shintani, Y; Yokoi, M; Goto, T; Oishi, Y; Ikehara, N; Sugiura, M; Ohta, K; Hashimoto, H; Yajima, K; Seo, Y

    JOURNAL OF ECHOCARDIOGRAPHY   Vol. 23 ( 1 ) page: 24 - 40   2025.3

  10. Efficacy of Tranilast in Preventing Exacerbating Cardiac Function and Death from Heart Failure in Muscular Dystrophy Patients with Advanced-stage Heart Failure: A Single-arm, Open-label, Multicenter Study. Reviewed International journal

    Tsuyoshi Matsumura, Takayasu Fukudome, Yasufumi Motoyoshi, Akinori Nakamura, Satoshi Kuru, Kazuhiko Segawa, Ruriko Kitao, Chigusa Watanabe, Takuhisa Tamura, Toshiaki Takahashi, Hiroya Hashimoto, Masahiro Sekimizu, Akiko M Saito, Masanori Asakura, Koichi Kimura, Yuko Iwata

    Orphanet Journal of Rare Diseases   Vol. 20 ( 1 ) page: 13 - 13   2025.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s13023-025-03538-1

    Web of Science

    Scopus

    PubMed

    researchmap

  11. Sirolimus treatment for intractable vascular anomalies (<scp>SIVA</scp>): An open‐label, single‐arm, multicenter, prospective trial Reviewed International journal

    MICHIO OZEKI, Saori Endo, Shiho Yasue, Ryuta Asada, Akiko M. Saito, Hiroya Hashimoto, Shigeru Ueno, Shoji Watanabe, Motoi Kato, Kyoichi Deie, Shunsuke Nosaka, Mikiko Miyasaka, Akihiro Umezawa, Kentaro Matsuoka, Mototoshi Kato, Tatsuo Kuroda, Takanobu Maekawa, Satoshi Hirakawa, Taizo Furukawa, Shigehisa Fumino, Tatsuro Tajiri, Junkichi Takemoto, Naonori Kawakubo, Akihiro Fujino

    Pediatrics International   Vol. 67 ( 1 ) page: e70002   2025.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs.</jats:p></jats:sec>

    DOI: 10.1111/ped.70002

    Web of Science

    PubMed

    researchmap

▼display all

Books 1

  1. 臨床研究の歩き方 : これであなたも研究者!

    永井, 宏和( Role: Contributor)

    診断と治療社  2025.1  ( ISBN:9784787826503

     More details

    Total pages:x, 183p   Language:Japanese

    CiNii Research

    researchmap

Presentations 1

  1. Corrections of confidence interval for differences in restricted mean survival times in clinical trials with small sample sizes

    Hashimoto H., Kada A.

    The 46th Annual Conference of the International Society for Clinical Biostatistics  2025.8.26 

     More details

    Event date: 2025.8

    Language:English   Presentation type:Poster presentation  

    researchmap

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. Development of Statistical Analysis Methods Using Restricted Mean Survival Time in Small Clinical Trials

    Grant number:23K09602  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator 

    Grant amount:\3770000 ( Direct Cost: \2900000 、 Indirect Cost:\870000 )

    researchmap

  2. Development of a novel treatment for occupational dystonia and validation of its usefulness.

    Grant number:23K10535  2023.4 - 2027.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  3. Innovative smartphone psychotherapy targeting both fear of recurrence and persistent chronic pain after curative cancer resection

    Grant number:23K25738  2023.4 - 2027.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  4. 多機能性T細胞を標的とした免疫学的寛解治療法の確立

    Grant number:21K08443  2021.4 - 2025.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    前田 伸治, 橋本 大哉

      More details

    Authorship:Coinvestigator(s) 

    R3年度、NOGマウスの多機能性T細胞(PFC-T cells)の実験では、NOGマウスにヒト末梢血を移入し、day7にIL-2/IL-2抗体複合体を腹腔内注射し、さらにCTLA4-Igを持続投与させることで、ヒトT細胞が多機能性T細胞に分化する(PFC-T cells in vivo model)。我々が確立したヒトPFC-T cells in vivo modelを利用して、この脾臓からヒトT細胞を採取(hNOG-PFC-Tcells)し、以後の解析にもちいるため凍結保存した。また、比較コントロールとして、MHC発現を抑制したΔMHC-NOGマウスを用いて、同様に(ヒト末梢血を移入し、day7にIL-2/IL-2抗体複合体を腹腔内注射し、さらにCTLA4-Igを持続投与)行い、脾臓からヒトT細胞を採取、凍結保存した。
    ヒトリウマチ性疾患におけるPFCーT cellsの解析の研究では、関節リウマチ初診の末梢血、SLE初診の末梢血、および健常人の末梢血のMass cytometryによる高次元データを解析中である。

    researchmap